Search

Your search keyword '"hemorrhagic events"' showing total 2 results
Start Over Descriptor "hemorrhagic events" Publisher ivyspring international publisher
2 results on '"hemorrhagic events"'

1. Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age

Author

Toshiyuki Suzuki, Mitsuhiro Nakamura, Natsumi Ueda, Ryogo Umetsu, Yasutomi Kinosada, Yamato Kato, Junko Abe, Yoko Nakayama, Hideko Nagasawa, and Yukiya Suzuki

Subjects
Adult, Male, Aging, Databases, Factual, Renal function, Hemorrhage, hemorrhagic events, Kidney, computer.software_genre, Antithrombins, Dabigatran, Adverse Event Reporting System, Atrial Fibrillation, Odds Ratio, medicine, Adverse Drug Reaction Reporting Systems, Humans, dabigatran, Stroke, Aged, Aged, 80 and over, Database, United States Food and Drug Administration, business.industry, Age Factors, Warfarin, Anticoagulants, Atrial fibrillation, General Medicine, Odds ratio, Middle Aged, medicine.disease, United States, warfarin, adverse event reporting system, medicine.anatomical_structure, Female, Gastrointestinal Hemorrhage, business, Intracranial Hemorrhages, computer, Research Paper, medicine.drug
Abstract

Dabigatran and warfarin are oral anticoagulant drugs widely used for the prevention of stroke in patients with atrial fibrillation. The objective of this study was to evaluate the interaction between aging and dabigatran- and warfarin-induced gastrointestinal (GI) and nervous system hemorrhage using data available in the FDA Adverse Event Reporting System (FAERS) database. We analyzed reports of hemorrhagic events in the GI and nervous system recorded in the FAERS database between 2004 and 2014 using an adjusted reporting odds ratio (ROR). We demonstrated that dabigatran-associated GI hemorrhage was significantly increased in patients over the age of 80 years. The RORs of dabigatran increased with increasing age, although aging had little effect on warfarin-associated GI hemorrhage. The ROR for anticoagulant-associated nervous system hemorrhage was not significantly affected by aging, as compared to GI hemorrhage. Our results indicate that the excretion of dabigatran may be affected by aging, as compared to warfarin, likely due to renal function decline. Our results emphasize the need for physicians to closely monitor GI bleeding in aging patients, because it is closely related to renal function deterioration.

Published
2015

2. Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age.

Author

Abe J, Umetsu R, Kato Y, Ueda N, Nakayama Y, Suzuki Y, Suzuki T, Nagasawa H, Kinosada Y, and Nakamura M

Subjects
Adult, Adverse Drug Reaction Reporting Systems, Age Factors, Aged, Aged, 80 and over, Aging physiology, Anticoagulants pharmacokinetics, Antithrombins pharmacokinetics, Atrial Fibrillation drug therapy, Dabigatran pharmacokinetics, Databases, Factual, Female, Gastrointestinal Hemorrhage chemically induced, Humans, Intracranial Hemorrhages chemically induced, Kidney physiopathology, Male, Middle Aged, Odds Ratio, United States, United States Food and Drug Administration, Warfarin pharmacokinetics, Anticoagulants adverse effects, Antithrombins adverse effects, Dabigatran adverse effects, Hemorrhage chemically induced, Warfarin adverse effects
Abstract

Dabigatran and warfarin are oral anticoagulant drugs widely used for the prevention of stroke in patients with atrial fibrillation. The objective of this study was to evaluate the interaction between aging and dabigatran- and warfarin-induced gastrointestinal (GI) and nervous system hemorrhage using data available in the FDA Adverse Event Reporting System (FAERS) database. We analyzed reports of hemorrhagic events in the GI and nervous system recorded in the FAERS database between 2004 and 2014 using an adjusted reporting odds ratio (ROR). We demonstrated that dabigatran-associated GI hemorrhage was significantly increased in patients over the age of 80 years. The RORs of dabigatran increased with increasing age, although aging had little effect on warfarin-associated GI hemorrhage. The ROR for anticoagulant-associated nervous system hemorrhage was not significantly affected by aging, as compared to GI hemorrhage. Our results indicate that the excretion of dabigatran may be affected by aging, as compared to warfarin, likely due to renal function decline. Our results emphasize the need for physicians to closely monitor GI bleeding in aging patients, because it is closely related to renal function deterioration.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results